Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
ConclusionsThe final analysis from the PMS study confirms previous findings suggesting that idarucizumab can safely and effectively reverse the anticoagulant effects of dabigatran in Japanese patients in clinical practice. The results support the continued use of idarucizumab in Japan.Trial RegistrationThis study is registered with ClinicalTrials.gov (NCT02946931).Graphical Abstract
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
More News: Bleeding | Cardiology | Drugs & Pharmacology | Emergency Medicine | Heart | Japan Health | Pradaxa | Study